Orforglipron for Sleep Apnea: Lilly’s Weight Loss Pill Cut Breathing Pauses by Up to 44 Percent

For millions of people, the standard treatment for a serious sleep disorder looks like something out of a science fiction film: a mask over the nose or face, a hose and a humming machine on the nightstand. It works. Plenty of people still struggle to use it every night. Now a once-daily pill may be heading toward that nightstand instead. On 9 November 2026 Eli Lilly presented results showing that its oral weight loss drug orforglipron, sold as Foundayo, substantially reduced the severity of obstructive sleep apnea in adults with obesity or overweight.

The data from the ATTAIN-OSA programme were presented at the American Heart Association Scientific Sessions in Chicago and published at the same time in JAMA. Before you start rearranging your bedroom, here is what the trials actually found and where the limits are.

What sleep apnea does to your night

In obstructive sleep apnea, the upper airway repeatedly collapses during sleep. Breathing becomes shallow or stops for a few seconds, oxygen levels fall and the brain briefly wakes you to restart it. Most people do not remember these micro-awakenings. They just feel exhausted the next day. Often it is their partner who reports the snoring.

Doctors measure severity with the apnea-hypopnea index, or AHI: the number of breathing pauses and shallow-breathing episodes per hour of sleep. The participants in these trials started with averages of about 51 and 58 events per hour. In plain terms, their breathing was disrupted roughly once a minute all night long.

Lilly estimates that sleep apnea affects about 936 million adults worldwide, most of them undiagnosed. That figure comes from the company’s press material, so treat it as an estimate rather than a census. What is well established is the link to excess weight: fat tissue around the neck and upper airway makes collapse more likely.

What the ATTAIN-OSA trials found

ATTAIN-OSA consisted of two 52-week, randomised, double-blind, placebo-controlled studies. Study 1 enrolled 363 adults who could not or would not use positive airway pressure therapy, the mask-and-machine approach known as PAP or CPAP. Study 2 enrolled 349 adults who were already using PAP. People with diabetes were excluded. Everyone received diet and lifestyle counselling. Participants started on a low dose and were increased step by step to the highest dose they tolerated.

The headline results, according to Lilly’s figures:

In Study 1, without PAP, the AHI fell by 21.1 events per hour on orforglipron, a reduction of 43.8 percent, compared with 4.3 events per hour on placebo. In Study 2, with PAP, it fell by 18.3 events per hour, or 27.5 percent, compared with 5.5 on placebo. About 31.5 percent of participants in Study 1 reached remission or mild sleep apnea. In Study 2 that figure was 19.6 percent.

Body weight dropped by 11.5 percent in Study 1 and 11.2 percent in Study 2, compared with 1.8 and 0.9 percent on placebo. Markers of inflammation and systolic blood pressure also improved. Lilly notes that the blood pressure result was not controlled for multiple statistical testing, so read it as supportive rather than conclusive.

Presenter Vaishnavi Kundel of the Icahn School of Medicine at Mount Sinai noted, according to Healio, that CPAP typically lowers systolic blood pressure by only about 2 to 3 mm Hg. In these trials the drop was 7 to 8 mm Hg. That comparison is between different studies, though, not a head-to-head trial.

Why a pill is a big deal

This is not the first weight loss drug to tackle sleep apnea. Tirzepatide, sold as Zepbound and also made by Lilly, was approved in the US in 2024 for moderate to severe sleep apnea in adults with obesity. But it is a weekly injection. Orforglipron is a small-molecule GLP-1 drug you swallow once a day. It received US approval for chronic weight management in April 2026, according to Healio.

Michael Grandner, a sleep researcher at the University of Arizona, told Healio: “There are no current oral treatments for sleep apnea.” He called a pill a potential “game changer”. Note his disclosed consulting ties to several sleep and health companies, which Healio lists.

The appeal is easy to understand. CPAP is highly effective when used, but many people find the mask uncomfortable or give up over time. A pill does not require you to sleep like Bane from The Dark Knight Rises. Our point here is about the equipment, not about anyone who uses it: if CPAP works for you, it remains the established standard.

The limits you should know about

Several caveats matter. First, the drug improved sleep apnea but did not cure it for most people. Even in the better-performing group, roughly two thirds did not reach remission or mild disease. Second, the benefit appears closely tied to weight loss. The trials were not designed to show whether the drug helps people with sleep apnea who are not overweight.

Third, side effects. As with other GLP-1 medicines, the most common adverse events were gastrointestinal: nausea, diarrhoea, constipation, indigestion and vomiting, mostly mild to moderate. In Study 1, 12.2 percent of participants on orforglipron stopped treatment because of side effects, compared with 3.8 percent on placebo. In Study 2 the figures were 6.8 versus 0.6 percent. The drug also carries the class warnings familiar from other GLP-1 medicines, including a contraindication for people with a personal or family history of certain thyroid tumours.

Fourth, approval. Orforglipron is not yet approved for sleep apnea. Lilly says it plans to submit an application to the US Food and Drug Administration by the end of 2026. Approval timing and pricing for this use remain open. Results also come from company-funded trials, which is normal for drug development but worth keeping in mind.

What this means beyond the bedroom

Our reading, which is interpretation rather than fact: GLP-1 medicines are steadily turning from “weight loss drugs” into treatments for the many conditions that excess weight drives, from heart disease to joint pain and now sleep. That is good news for patients who have few options. It also raises old questions about cost, access and whether a pill should replace lifestyle support or simply sit beside it.

For now, the practical takeaway is simple. If you snore loudly, wake up exhausted or have been told you stop breathing at night, the first step is not a prescription. It is a diagnosis. The pill may be coming. The sleep study comes first.

This article is for general information only and does not replace advice from a doctor. If you think you may have sleep apnea, please talk to a qualified healthcare professional.